BioInvent has developed two patented technology platforms that will enable identification of relevant human antibodies and disease targets – the unique F.I.R.S.T.™ development tool and the n-CoDeR® antibody library, containing completely human antibodies. Basically, drug candidates can be selected that bind very specifically and firmly to their target structures. Our technology platforms are used to develop antibody-based drugs in collaboration with our partners as well as in BioInvent’s proprietary projects.
In addition, BioInvent offers a cGMP-certified manufacturing facility for the production of antibodies. We also provide biological and preclinical expertise, primarily in the field of cancer biology and tumour immunology, to both commercial and scientific collaborations.